HypogonadismPhase 2REVIVENCT07535905
Clinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients
A Phase 2 study testing Tamoxifen in people with Hypogonadism and Prostate Cancer, run by University Health Network, Toronto at 1 site in Canada.
Trial summary
Androgen deprivation therapy (ADT) is a cornerstone therapy in the treatment of curable prostate cancer (PCa). However, ADT often leads to a protracted testosterone recovery period in most men or absence of complete recovery in 10-25% of cases. Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Hypogonadism, Prostate Cancer
- What is being tested?
- Tamoxifen
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 96 participants
- Where
- 1 siteCanada
- Study dates
- 31 Dec 2026to Oct 2030
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- At least 18 years of age;
- Ability to understand the purposes and risks of the trial and has signed a written informed consent form. Have a diagnosis of prostate cancer;
- Patient received ADT for a duration of either 6 or 18-36 months as part of the curative intent treatment. Curative intent prostate cancer patients who completed ADT and have had no further ADT for the length of the last ADT injection depot formulation (e.g., if the last ADT injection depot formulation is for 3 months, the patient must have no ADT for 3 months after last injection)
- Have effectively castrated testosterone (< 1.7 nmol/L [50 ng/dL]) within 6 weeks of enrollment;
- ECOG Performance status 0-2
Who cannot join
- Harbouring certain CYP2D6 alleles (i.e. CYP2D6*4) or from the chronic use of a CYP2D6 inhibitor(s);
- History of blood clots (venous thromboembolism or pulmonary embolism);
- History of stroke or transient ischemic attack (TIA);
- Reduced liver function within last 120 days prior to enrolment, defined as follows:
- Total Bilirubin: 1.5 > upper limit of normal (ULN) (For Gilbert's syndrome, if total bilirubin is <1.5 x ULN, measure direct and indirect bilirubin. If direct bilirubin is greater than 1.5 x ULN, participant is ineligible;
- AST(SGOT) and ALT(SGPT): > 2.5x ULN;
Show all 16Show fewer
- Or other liver disease as deemed ineligible by the investigator
- Baseline QT/QTc > 500ms;
- Active therapy with selective serotonin reuptake inhibitor (SSRI) antidepressants (e.g. paroxetine, a known CYP2D6 inhibitor);
- Active therapy with coumarin-type anticoagulants;
- Active therapy with cytotoxic agents;
- Active therapy with aromatase inhibitors;
- Other invasive malignancy within the last 5 years, other than squamous or basal cell carcinoma of the skin;
- Treatment with a non-approved or experimental drug during the 3 months before informed consent;
- Patients known to have one of the following hereditary illnesses; galactose- intolerance, Lapp lactase deficiency or glucose-galactose malabsorption;
- Any other significant concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the participant in this trial;
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
University Health Network - Princess Margaret Cancer Center
Toronto, Ontario, M5G 2M9
Alejandro Berlin, MD, 416-946-4501 ext. 5813, alejandro.berlin@uhn.ca
About this study
Official title: Phase II Controlled Clinical Trial to Test Efficacy and Observe Longitudinal Effects of Tamoxifen for Testosterone Recovery in Medically Castrated Prostate Cancer Patients
Androgen deprivation therapy (ADT) is a cornerstone therapy in the treatment of curable prostate cancer (PCa). However, ADT often leads to a protracted testosterone recovery period in most men or absence of complete recovery in 10-25% of cases. The hypogonadal state has significant psychosocial and physical side effects. Therefore, limiting ADT effect's duration beyond the prescribed castration period is very compelling to patients and providers alike.
Tamoxifen, a well-established selective estrogen receptor modulator, offers a novel and cost-effective approach to accelerate testosterone recovery in men with secondary hypogonadism. This project addresses a critical gap in global cancer care by evaluating Tamoxifen as a viable solution for reducing the burden of delayed testosterone recovery and its associated side effects, particularly in resource-limited settings.
- Conditions
- Hypogonadism, Prostate Cancer
- Being tested
- Tamoxifen
- Medical subject headings
- Hypogonadism, Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TamoxifenDrug
Selective estrogen receptor modulator, oral tablet
| Study group | Role | What they receive |
|---|---|---|
| Non-Experimental Intervention: Observation | No intervention | Participant will not receive intervention after treatment with ADT. Per routine care, participant will undergo observation for testosterone recovery |
| Experimental Intervention: Tamoxifen | Experimental | Participant will take 2 tamoxifen pills by mouth, every day, for a total of 40 mg each day. The duration of tamoxifen treatment will depend on the duration of the participant's previous ADT treatment. If the participant received ADT treatment for 6 months, they will receive daily Tamoxifen for 3 months. If the participant received ADT treatment for 18-36 months, they will receive daily Tamoxifen for 6 months. Receives: Drug: Tamoxifen |
What is being measured
The primary outcome is the main question the study is designed to answer.
Normal Testosterone Recovery
Proportion of participants with normal testosterone levels (i.e. total testosterone > 7.7nmol/L [222 ng/dL])
Measured: 6 months after starting intervention
Secondary outcomes (11)
Disease Control
Measurement of PSA levels in blood
Measured: From enrollment to 2 years after starting treatment
Patient-Reported Toxicities
Collection and assessment of adverse events as per PRO-CTCAE version 6.0
Measured: From enrollment to 2 years after starting treatment
Non-Castrated Testosterone Recovery
Proportion of participants with non-castrated testosterone levels (i.e. 50-222 ng/dL])
Measured: From enrollment to 2 years after starting treatment
Time to Testosterone Recovery
How long it takes for participants to reach non-castrated and normal testosterone levels
Measured: From enrollment to 2 years after starting treatment
Urinary Function (Patient-Reported Quality of Life)
Participant completion of the EPIC-26 questionnaire
Measured: From enrollment to 2 years after starting treatment
Bowel Function (Patient-Reported Quality of Life)
Participant completion of the EPIC-26 questionnaire
Measured: From enrollment to 2 years after starting treatment
Sexual Function (Patient-Reported Quality of Life)
Participant completion of the EPIC-26 questionnaire
Measured: From enrollment to 2 years after starting treatment
Fatigue (Patient-Reported Quality of Life)
Participant completion of the PROMIS-Fatigue Short Form questionnaire
Measured: From enrollment to 2 years after starting treatment
Cognitive Function (Patient-Reported Quality of Life)
Participant completion of the FACT-Cog questionnaire
Measured: From enrollment to 2 years after starting treatment
Depression (Patient-Reported Quality of Life)
Participant completion of the PROMIS Emotional Distress-Depression Short Form questionnaire
Measured: From enrollment to 2 years after starting treatment
Overall Health (Patient-Reported Quality of Life)
Participant completion of the EQ-5D-5L questionnaire
Measured: From enrollment to 2 years after starting treatment
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Apr 2026
- Study start31 Dec 2026 (estimated)
- Primary completionOct 2030 (estimated)
- Study completionOct 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HypogonadismStudies of the same condition, open and under way.
- More trials run by University Health Network, TorontoThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 96 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Health Network, Toronto
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07535905
- Sponsor's protocol ID
- 25-5742
- Other IDs
- BERLIN-02
- Acronym
- REVIVE
- Status last verified
- Oct 2026
- First submitted
- 27 Mar 2026
- Last updated
- 22 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Phase II Controlled Clinical Trial to Test Efficacy and Observe Longitudinal Effects of Tamoxifen for Testosterone Recovery in Medically Castrated Prostate Cancer Patients
- ClinicalTrials.gov ID
- NCT07535905
- Acronym / sponsor ID
- REVIVE / 25-5742
- Conditions
- Hypogonadism, Prostate Cancer
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 96 participants (estimated)
- Lead sponsor
- University Health Network, TorontoUniversity, hospital or other
- Study start
- 31 Dec 2026 (estimated)
- Primary completion
- Oct 2030 (estimated)
- Study completion
- Oct 2030 (estimated)
- First posted
- 17 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Androgen deprivation therapy (ADT) is a cornerstone therapy in the treatment of curable prostate cancer (PCa). However, ADT often leads to a protracted testosterone recovery period in most men or absence of complete recovery in 10-25% of cases. The hypogonadal state has significant psychosocial and physical side effects. Therefore, limiting ADT effect's duration beyond the prescribed castration period is very compelling to patients and providers alike.
Tamoxifen, a well-established selective estrogen receptor modulator, offers a novel and cost-effective approach to accelerate testosterone recovery in men with secondary hypogonadism. This project addresses a critical gap in global cancer care by evaluating Tamoxifen as a viable solution for reducing the burden of delayed testosterone recovery and its associated side effects, particularly in resource-limited settings.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Non-Experimental Intervention: Observation | No intervention | –Participant will not receive intervention after treatment with ADT. Per routine care, participant will undergo observation for testosterone recovery |
| Experimental Intervention: Tamoxifen | Experimental | Drug: TamoxifenParticipant will take 2 tamoxifen pills by mouth, every day, for a total of 40 mg each day. The duration of tamoxifen treatment will depend on the duration of the participant's previous ADT treatment. If the participant received ADT treatment for 6 months, they will receive daily Tamoxifen for 3 months. If the participant received ADT treatment for 18-36 months, they will receive daily Tamoxifen for 6 months. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- At least 18 years of age;
- Ability to understand the purposes and risks of the trial and has signed a written informed consent form. Have a diagnosis of prostate cancer;
- Patient received ADT for a duration of either 6 or 18-36 months as part of the curative intent treatment. Curative intent prostate cancer patients who completed ADT and have had no further ADT for the length of the last ADT injection depot formulation (e.g., if the last ADT injection depot formulation is for 3 months, the patient must have no ADT for 3 months after last injection)
- Have effectively castrated testosterone (< 1.7 nmol/L [50 ng/dL]) within 6 weeks of enrollment;
- ECOG Performance status 0-2
Key exclusion criteria (16 listed)
- Harbouring certain CYP2D6 alleles (i.e. CYP2D6*4) or from the chronic use of a CYP2D6 inhibitor(s);
- History of blood clots (venous thromboembolism or pulmonary embolism);
- History of stroke or transient ischemic attack (TIA);
- Reduced liver function within last 120 days prior to enrolment, defined as follows:
- Baseline QT/QTc > 500ms;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TamoxifenSelective estrogen receptor modulator, oral tablet | Drug | Experimental Intervention: Tamoxifen |
Primary outcome
Normal Testosterone Recovery
Time frame: 6 months after starting intervention
Proportion of participants with normal testosterone levels (i.e. total testosterone > 7.7nmol/L [222 ng/dL])
11 secondary outcomes
Disease Control
Time frame: From enrollment to 2 years after starting treatment
Patient-Reported Toxicities
Time frame: From enrollment to 2 years after starting treatment
Non-Castrated Testosterone Recovery
Time frame: From enrollment to 2 years after starting treatment
Time to Testosterone Recovery
Time frame: From enrollment to 2 years after starting treatment
Urinary Function (Patient-Reported Quality of Life)
Time frame: From enrollment to 2 years after starting treatment
Bowel Function (Patient-Reported Quality of Life)
Time frame: From enrollment to 2 years after starting treatment
Sexual Function (Patient-Reported Quality of Life)
Time frame: From enrollment to 2 years after starting treatment
Fatigue (Patient-Reported Quality of Life)
Time frame: From enrollment to 2 years after starting treatment
Cognitive Function (Patient-Reported Quality of Life)
Time frame: From enrollment to 2 years after starting treatment
Depression (Patient-Reported Quality of Life)
Time frame: From enrollment to 2 years after starting treatment
Overall Health (Patient-Reported Quality of Life)
Time frame: From enrollment to 2 years after starting treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2026.
Related trials for Hypogonadism
RecruitingObservational study
Anticipated Stigma, Illness Identity, and Quality of Life in Male Hypogonadism
Hypogonadism, Male, Endocrine Disease
Recruiting
Feasibility of a Digital Self-help Program for Functional Hypothalamic Amenorrhea (HEAL-FHA Pilot)
Functional Hypothalamic Amenorrhea
RecruitingPhase 3
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
Hypogonadism, Male
RecruitingPhase 4
Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance
Prostate Cancer, Hypogonadism, Male
RecruitingObservational study
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
Testicular Cancer, Survivorship
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Tamoxifen in people with Hypogonadism and Prostate Cancer, run by University Health Network, Toronto at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alejandro Berlin, MD (416-946-4501 ext. 5813, alejandro.berlin@uhn.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Normal Testosterone Recovery (time frame: 6 months after starting intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.